Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Can a Daily Dose of Creatine Prevent Neurodegeneration?
14 June 2000. Creatine, increasingly popular as a dietary and exercise supplement, has shown the ability to counteract laboratory models of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), Huntington's disease, and Parkinson's disease. A significant new study shows that it slows the pathological and behavioral effects of a transgenic model of Huntington's disease, an autosomal dominant neurodegenerative disorder that has both motor and mental effects.

In the June 15 issue of the Journal of Neuroscience, Robert Ferrante, Flint Beal and associates describe experiments in which they added creatine supplement to the feed of mice expressing part of the human Huntington's gene. These mice typically show physiological and behavioral signs resembling human Huntington's at an early age. In the mice fed creatine, there was significant protective effect by a number of measures, e.g., increased length of survival, decreased overall brain atrophy and body weight loss, delayed atrophy of striatal neurons, delayed formation of aggregates of the gene product huntingtin, and improved motor performance.

The idea behind using creatine in Huntington's, as well as other neurodegenerative diseases, is that these disorders may interfere with energy metabolism and thereby initiate apoptotic mechanisms. Creatine, in the form creatine phosphate, functions like ATP, storing high-energy phosphate bonds. It has been suggested that supplemental creatine can thus help buffer against energy metabolism perturbations caused by neurodegenerative disease processes, including those caused by Alzheimer's.-Hakon Heimer.

Comment by Ethan Signer-Cure HD Initiative
This latest in a series of studies on creatine from the Beal group demonstrates a benefit in a transgenic mouse model of Huntington's disease (HD), similar to that seen in their earlier work with a transgenic mouse model of amyotrophic lateral sclerosis (ALS) and pharmacological mouse models of HD and Parkinson's disease (PD). The benefit is substantial if modest, including improvement in a variety of behavioral and metabolic markers as well as a 20 percent increase in survival, although the inverted dose-response curve remains puzzling. The extent of the benefit and its effect on neurodegenerative diseases as different genetically as HD, ALS and PD presumably reflect mitigation of compromised energy metabolism that is secondary to the primary gene defect, and therefore suggest creatine could benefit other neurodegenerative diseases (such as Alzheimer's disease?) as well. Although a definitive trial of creatine in HD itself has yet to be carried out, it is significant that creatine is considered completely safe for humans and is widely available over the counter without prescription.

Ethan R. Signer
Professor of Biology Emeritus, MIT
Executive Director, Cure HD Initiative, Hereditary Disease Foundation
230 Park Avenue, 7th floor
New York, NY 10169
tel 917/368-5498 fax 917/368-5499
signer@mit.edu


Reference:Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000 Jun 15;20(12). Abstract

 
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad